The company's CEO, Marc Voigt, said: "We are very disappointed and surprised with the outcome of the futility analysis, in light of efti's performance in every other clinical trial. […] We are currently conducting a comprehensive review of the available data to better understand the results and determine the appropriate next steps for the program."

Immutep Limited (ASX: IMM) – Trading Halt Trading in the securities of Immutep Limited (‘IMM’) will be halted at the request of IMM, pending the release of an announcement by IMM. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 11 March 2026; or • the release of the announcement to the market. IMM’s request for a trading halt is attached below for the information of the market. Issued by ASX Compliance

https://www.marketindex.com.au/asx/imm?src=search-all

IMM - Holders had 7 days 6th till 13th Mar then Bang the shares slide down the 'elevator'.. So speculators lost their shirts there.

Return (inc div)   1yr: -84.21%   3yr: -44.16% pa   5yr: -32.73% pa

Microcap $66Mill

No profit organisation!

please visit www.immutep.com.

IMM still has a pipeline of trials..

threads/ann-immutep-quarterly-act

• Release Date: 29/01/26 11:36
• Summary: Immutep Quarterly Activities Report and Appendix 4C
• IMM Estimate 7.7 quarters of funding. here:
•